紫杉醇、去甲长春花碱分别联合顺铂治疗晚期乳腺癌的临床研究  

THE CLINICAL TRIAL OF CHEMOTHERAPY BY VINORELBINE OR PACLITAXEL PLUS CIS PLATIN ON ADVANCED BREAST CANCER

作　　者：钱志英[1] 吴罕利[1] 朱敬华[1] 

机构地区：[1]江苏省肿瘤医院,江苏南京210009

出　　处：《肿瘤研究与临床》2003年第5期311-313,共3页Cancer Research and Clinic

摘　　要：目的 :观察国产紫杉醇 (紫素 )及去甲长春花碱 (盖诺 )分别与顺铂组成联合方案 ,治疗复发或有远处转移乳腺癌的疗效、毒副作用及临床受益反应 (clinical benefit response,CBR)。方法 : 期～ 期乳腺癌患者 75例 ,分为紫素组 (紫素 +顺铂 ) 3 6例、盖诺组 (盖诺 +顺铂 ) 3 9例。结果 :紫素组有效率 63 .9% (2 3 / 3 6) ,中位缓解期 9个月 (6个月～ 19个月 ) ,CBR率 52 .8% (19/ 3 6) ;盖诺组有效率 56.4% (2 2 / 3 9) ,中位缓解期 7个月 (5.5个月～ 14个月 ) ,CBR率 46.2 % (18/ 3 9)。组间疗效、缓解时间及 CBR无显著性差异 (P>0 .0 5)。主要毒副作用为骨髓抑制、消化道反应和静脉炎 ,均为可逆性。结论 :紫素、盖诺分别与顺铂组成二药联合方案对复发或有远处转移的、特别是蒽环类耐药的晚期乳腺癌疗效确切 ,毒副作用较轻 ,组间无显著性差异 。Objective:To observe the effect, toxicity and clin ical benefit response (CBR) of chemotherapy by Vinorelbine or Taxol combined wit h Cisplatin on relapsed or distant metastasized breast cancer.Methods: 75 cases of advanced breast cancer (stage Ⅲ～Ⅳ) were treated.36 patients received TP regimen (Taxol+PDD) and 39 patients received NP regimen (NVB+PDD). Results:In TP group, the response rate was 63.9 %(23/36) and in NP group, the response rate was 56.4 %(22/39). The median remission time were 9 (6～19) months and 7 (5.5～14) months. The CBR was 52.8 %(19/36) and 46.2 %(18/ 39). The efficacy, median remission time and CBR were not statistically signific ant (P>0.05). The main side effects were neutropenia, gastrointestinal trac t reaction and local venous toxicity.Conclusion:The combined reg imen of Taxol plus CDDP and NVB plus CDDP were effective to patients with advanc ed breast cancer who suffered from relapse or distant metastasis, especially to those with ADM resistant, and were less toxic. There were no obvious difference among the two groups. The two regimens can be applied to the fist line chemother apy.

关 键 词：乳腺癌 药物疗法 紫杉醇 去甲长春花碱 顺铂 

分 类 号：R736.1[医药卫生—肿瘤]